ChitogenX Inc. (CHNXF) Stock

About ChitogenX Inc.

ChitogenX Inc. is a biologics firm focused on orthopedic and sports medicine, committing its efforts to pioneering novel soft tissue repair technologies. The company's primary objective is to elevate the efficacy of sports medicine surgical procedures through its research and development. Its developmental pipeline includes a range of specialized products: Ortho-R, a specific formulation designed for rotator cuff injuries; Ortho-M, a biopolymer addressing meniscus repair; Ortho-C, another biopolymer for the regeneration of articular cartilage; and Ortho-V, a biopolymer developed to facilitate the healing of osteoarthritis. Additionally, they are advancing ORTHO-T, a biopolymer formulation engineered for tendon healing and regeneration. Previously known as Ortho Regenerative Technologies Inc., the company adopted its current name, ChitogenX Inc., in September of 2022. Established in 2015, ChitogenX maintains its headquarters in Kirkland, Canada.

ChitogenX Inc. is headquartered in CA.

ChitogenX Inc. (CHNXF) stock trades at $0.01 with a market capitalization of $627628. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.23, reflecting a net loss over the last twelve months, a negative price-to-book of -0.06, reflecting negative shareholders' equity, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $0.00 and $0.02, and currently trades 50.0% below its 52-week high.

On profitability, ChitogenX Inc. generates a return on equity (ROE) of 19.40% (not meaningful, as shareholders' equity is negative), return on capital employed of 100.04%.

Official website: www.chitogenx.com